Back
Regulus Therapeutics 10K Form
Sell
35
RGLS
Regulus Therapeutics
Last Price:
1.99
Seasonality Move:
-26.42%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-05-09 | 10Q | RGLS/Regulus Therapeutics Quarterly |
| 2023-11-09 | 10Q | RGLS/Regulus Therapeutics Quarterly |
| 2023-08-08 | 10Q | RGLS/Regulus Therapeutics Quarterly |
| 2023-05-11 | 10Q | RGLS/Regulus Therapeutics Quarterly |
| 2022-11-14 | 10Q | RGLS/Regulus Therapeutics Quarterly |
| 2022-08-11 | 10Q | RGLS/Regulus Therapeutics Quarterly |
Receive RGLS News And Ratings
See the #1 stock for the next 7 days that we like better than RGLS
RGLS Financial Statistics
Sales & Book Value
| Annual Sales: | $10.01M |
|---|---|
| Cash Flow: | $-8.97M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $1.64 |
| Price / Book: | 1.22 |
Profitability
| EPS (TTM): | -1.45000 |
|---|---|
| Net Income (TTM): | $-31.37M |
| Gross Margin: | $0 |
| Return on Equity: | 0% |
| Return on Assets: | 0% |
Regulus Therapeutics Earnings Forecast
Key Regulus Therapeutics Financial Ratios
Regulus Therapeutics Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | RGLS |
| CUSIP: | 75915K |
| Website: | regulusrx.com |
Debt
| Debt-to-Equity Ratio: | 0 |
|---|---|
| Current Ratio: | 0 |
| Quick Ratio: | 0 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
RGLS Technical Analysis vs Fundamental Analysis
Sell
35
Regulus Therapeutics (RGLS)
is a Sell
Is Regulus Therapeutics a Buy or a Sell?
-
Regulus Therapeutics stock is rated a Sell
The current Regulus Therapeutics [RGLS] share price is $2.00. The Score for RGLS is 35, which is 30% below its historic median score of 50, and infers higher risk than normal.